CliffBio
small molecule

ALYFTREK

DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM

Loss of exclusivityAugust 2040latest FDA-listed patent expiry
CompanyVERTEX PHARMACEUTICALS INC

Drug detail

Brand nameALYFTREK
Active ingredientDEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM
Strength50MG;20MG;EQ 4MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2024
Marketing statusRX

Listed patents

PatentExpiresType
11873300August 2040substance, product
11066417February 2039substance, product
11866450February 2039use U-4463
8865902May 2032substance, product
9512079May 2032substance, product
9181192May 2032substance, product
10047053May 2032substance
RE50453July 2031substance, product
10081621March 2031product
11578062March 2031product
10646481August 2029product
11564916August 2029use U-4466
8415387November 2027use U-4463
8324242August 2027use U-4464
7776905June 2027substance, product
7495103May 2027substance, product
7645789May 2027substance, product
8623905May 2027substance, product
8598181May 2027use U-4463
10239867April 2027substance, product
11639347April 2027substance, product
10022352April 2027product
9974781April 2027product
8410274December 2026product
9931334December 2026product
8754224December 2026substance, product
9670163December 2026product
8354427July 2026use U-4091

Regulatory exclusivity

CodeExpires
ODE-536March 2033
ODE-526December 2031
NCEDecember 2029

More from VERTEX PHARMACEUTICALS INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ALYFTREK patent cliff — loss of exclusivity August 2040 | CliffBio